Logo

CLPT

ClearPoint Neuro, Inc.

CLPT

ClearPoint Neuro, Inc. • NASDAQ
$14.46 ▲ 0.14% (+0.02)
Market Cap $411.00 M
52w High $30.10
52w Low $9.76
Dividend Yield 0%
P/E -17.42
Volume 136.57K
Outstanding Shares 28.42M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $8.861M ▼ $10.876M ▼ $-5.891M ▼ -66.482% ▼ $-0.21 $-5.274M ▼
Q2-2025 $9.215M ▲ $11.236M ▼ $-5.837M ▲ -63.342% ▲ $-0.21 ▲ $-5.106M ▲
Q1-2025 $8.485M ▲ $11.295M ▲ $-6.026M ▼ -71.019% ▼ $-0.22 ▼ $-5.829M ▼
Q4-2024 $7.771M ▼ $10.366M ▲ $-5.386M ▼ -69.309% ▼ $-0.2 ▼ $-5.133M ▼
Q3-2024 $8.122M $10.019M $-4.974M -61.241% $-0.18 $-4.677M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $38.221M ▼ $60.357M ▼ $44.483M ▲ $15.874M ▼
Q2-2025 $41.541M ▲ $62.869M ▲ $43.126M ▲ $19.743M ▼
Q1-2025 $12.387M ▼ $30.07M ▼ $10.083M ▼ $19.987M ▼
Q4-2024 $20.104M ▼ $39.189M ▼ $13.8M ▲ $25.389M ▼
Q3-2024 $21.573M $40.193M $11.192M $29.001M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-5.891M ▼ $-3.121M ▼ $-199K ▼ $0 ▼ $-3.32M ▼ $-3.32M ▼
Q2-2025 $-5.837M ▲ $-2.552M ▲ $-91K ▲ $31.977M ▲ $29.334M ▲ $-2.643M ▲
Q1-2025 $-6.026M ▼ $-6.172M ▼ $-183K ▲ $-1.362M ▼ $-7.717M ▼ $-6.355M ▼
Q4-2024 $-5.386M ▼ $-1.243M ▼ $-263K ▼ $37K ▲ $-1.469M ▲ $-1.506M ▼
Q3-2024 $-4.974M $-1.199M $-12K $-10.061M $-11.272M $-1.211M

Revenue by Products

Product Q3-2024Q1-2025Q2-2025Q3-2025
Biologics And Drug Delivery
Biologics And Drug Delivery
 $0 ▲$0 ▲$0 ▲$0 ▲
Biologics And Drug Delivery Disposable Products
Biologics And Drug Delivery Disposable Products
 $0 ▲$0 ▲$0 ▲$0 ▲
Capital Equipment And Software
Capital Equipment And Software
 $0 ▲$0 ▲$0 ▲$0 ▲
Capital Equipment And Software Services
Capital Equipment And Software Services
 $0 ▲$0 ▲$0 ▲$0 ▲
Capital Equipment And Software Systems and Software Products
Capital Equipment And Software Systems and Software Products
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement ClearPoint Neuro is still in the “build” phase financially. Revenue has been growing from a very small base and gross profit is positive, which means the core products do have economic value. However, operating losses and net losses have been steady for several years, with no clear sign yet of a move toward profitability. The company is spending more than it earns, mainly on operating costs such as people, R&D, and commercial build‑out, which is typical for an early-stage, innovation‑driven medical device player but does keep pressure on future funding needs.

Balance Sheet

Balance Sheet The balance sheet is relatively simple and lean. The company holds a meaningful amount of cash compared with its total size, and debt levels are low and have been trending down, which reduces financial risk. Equity is positive but not large, reflecting accumulated losses over time. Overall, the company has some financial cushion, but not a thick one, so its ability to keep investing depends on maintaining access to capital if current losses continue.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, showing that the business is not yet self‑funding. Free cash flow is also negative, and capital spending is very light, so most of the cash burn comes from running and growing the business rather than from big equipment or facility investments. This pattern is typical for a company investing heavily in commercialization and R&D, but it means the company’s cash runway and any future capital raises are key variables to watch.

Competitive Edge

Competitive Edge ClearPoint has carved out a specialized niche in neurosurgery with real‑time MRI‑guided navigation, where it holds a unique regulatory and technological position. Its tools are deeply embedded in procedures that require very high precision, and the company is tightly integrated with dozens of pharma and biotech partners in cell and gene therapy delivery to the brain. This creates meaningful switching costs and a “platform” role, even though it competes indirectly with much larger, more diversified device companies. The business model is designed around recurring sales of disposables, so success depends heavily on procedure volumes and partner therapy adoption over time.

Innovation and R&D

Innovation and R&D Innovation is the clear strength of ClearPoint. The company is expanding from MRI-guided navigation into robotics, AI‑assisted brain modeling, and workflows that can be used in standard operating rooms, not only MRI suites. It also supports partners from preclinical research through clinical trials, giving it insight into next‑generation neuro therapies. The upside of this strategy is significant optionality if partner therapies succeed; the risk is that many programs can be delayed or fail, and the company must keep investing ahead of those outcomes while managing its limited financial resources.

Summary

ClearPoint Neuro combines a promising, highly specialized neuro‑navigation and drug‑delivery platform with the financial profile of an early‑stage, loss‑making medtech company. Strategically, it benefits from first‑mover status in real‑time MRI‑guided brain procedures, tight integration with cell and gene therapy developers, and a growing ecosystem of software, robotics, and AI tools. Financially, it remains small, unprofitable, and cash‑consuming, supported by a modest but not abundant balance‑sheet buffer. The long‑term story depends on broader clinical adoption, successful commercialization by its pharma and biotech partners, and the company’s ability to sustain its innovation push while managing ongoing cash burn and funding needs.

NEWS

November 20, 2025 · 5:00 PM UTC

ClearPoint Neuro Completes Acquisition of IRRAS

Read more

November 6, 2025 · 4:55 PM UTC

ClearPoint Neuro Reports Third Quarter 2025 Results

Read more

November 6, 2025 · 4:50 PM UTC

ClearPoint Neuro Announces Agreement to Acquire IRRAS

Read more

November 5, 2025 · 5:02 PM UTC

ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025

Read more

October 7, 2025 · 4:15 PM UTC

ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles

Read more